Stereotactic radiotherapy for soft tissue and bone sarcomas: real-world evidence.

Mateusz Jacek SpałekPaweł TeteryczAneta BorkowskaJan PoleszczukPiotr Rutkowski

Published in: Therapeutic advances in medical oncology (2022)

SRT provides excellent local control in STBS patients without significant toxicity. Patients with oligometastatic disease, lung metastases, and soft tissue sarcomas benefit the most from SRT. The dose escalation moderately enhances local control; however, it does not translate into better survival.

Keyphrases

soft tissue
end stage renal disease
ejection fraction
newly diagnosed
high grade
early stage
prognostic factors
radiation therapy
peritoneal dialysis
oxidative stress
small cell lung cancer
open label
radiation induced
bone mineral density
bone regeneration
body composition
study protocol